Technetium Tc-99M Sestamibi
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Technetium Tc-99M Sestamibi
- Technetium Tc-99m Sestamibi: From Myocardial Perfusion Imaging to Homozygous Familial Hypercholesterolemia
Technetium Tc-99m Sestamibi: From Myocardial Perfusion Imaging to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Technetium Tc-99m Sestamibi (Tc-99m MIBI) is a lipophilic cationic radiopharmaceutical diagnostic agent, widely used clinically for myocardial perfusion imaging (MPI/SPECT) and parathyroid scintigraphy. The TxGNN model predicts it may be applicable to Homozygous Familial Hypercholesterolemia (HoFH), with 0 clinical trials and 1 publication currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No regulatory licensing records in dataset (clinically used for myocardial perfusion imaging and parathyroid scintigraphy) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| US Market Status | No records in dataset |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological properties, Tc-99m Sestamibi is a lipophilic cationic complex that passively crosses cell membranes and accumulates in tissues with high mitochondrial density and large negative transmembrane potential — particularly myocardial cells, parathyroid adenoma cells, and certain tumor cells. It functions exclusively as a diagnostic imaging tracer, not as a therapeutic agent.
Homozygous Familial Hypercholesterolemia (HoFH) is a rare autosomal codominant disorder caused by biallelic loss-of-function mutations in the LDL receptor pathway, resulting in severely elevated LDL-C (typically >400 mg/dL from birth). The consequence is dramatically accelerated atherosclerosis, with patients developing symptomatic coronary artery disease in childhood or early adulthood. Because myocardial ischemia is the dominant end-organ threat in HoFH, Tc-99m MIBI myocardial perfusion imaging is a clinically relevant tool for risk stratification in these patients — exactly what the single supporting publication (PMID 26298359) describes.
The TxGNN high score most likely reflects an indirect knowledge-graph pathway: HoFH → extreme hypercholesterolemia → premature atherosclerosis → myocardial ischemia → MPI diagnostic application. This is a diagnostic applicability rather than a new therapeutic repurposing. The prediction does not suggest MIBI can treat HoFH or modify its disease course; it reflects the established role of MPI in cardiac risk assessment for high-risk lipid disorder patients.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26298359 | 2015 | Case Report | International Journal of Cardiology | Combined use of ¹⁸F-FDG PET and Tc-99m MIBI MPI in a patient with delayed-diagnosed HoFH; illustrates how cardiac perfusion imaging characterizes atherosclerotic and ischemic burden in HoFH patients |
US Market Information
No US FDA licensing records are available in the current dataset. This likely reflects a data retrieval gap rather than actual non-approval status — Tc-99m Sestamibi (Cardiolite®, Lantheus Medical Imaging) holds US FDA approval for cardiac perfusion imaging. A dataset update against FDA NDA records is recommended before drawing regulatory conclusions.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The sole supporting publication is a case report describing use of Tc-99m MIBI MPI within the clinical workup of an HoFH patient — this documents an existing diagnostic application, not a novel repurposing indication. There are no clinical trials and no mechanistic studies linking MIBI to HoFH pathophysiology beyond the indirect cardiovascular imaging pathway. As a diagnostic radiopharmaceutical with no therapeutic effect, framing this as a “drug repurposing” opportunity for HoFH requires conceptual clarification.
Note on higher-priority finding: The rank-2 prediction — Multiple Endocrine Neoplasia (MEN) — carries substantially stronger evidence (L3, 1 clinical trial, 20 publications, recommendation: Proceed with Guardrails) and reflects a well-established, 30-year-old clinical application of Tc-99m MIBI SPECT/CT for parathyroid adenoma localization in MEN1/MEN2A/MEN4 patients. A dedicated evaluation report for MEN is strongly recommended as the higher-priority target.
To proceed with HoFH, the following is needed:
- Clarification of framing: is the goal diagnostic utilization or therapeutic repurposing? (Tc-99m MIBI has no therapeutic mechanism relevant to lipid metabolism)
- US FDA NDA record retrieval for Cardiolite® to confirm approved indications and safety labeling
- Mechanism of action data from DrugBank (DB09161)
- TFDA prescribing information for formal safety assessment (Data Gap DG001)
- Prospective registry or observational data on MPI yield specifically in HoFH cohorts to establish diagnostic evidence beyond the current single case report
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.